SYROS PHARMACEUTICALS INC

SYRS Real Time Price USD
N/A
N/A
N/A
Price Data Unavailable for SYRS
Add to Watchlist
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of SYRS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
SYRS Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
SYRS Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
SYRS Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Whales13.33333333New1Increased2Held2Decreased1Closed34
Insider Trading

Quarterly net insider trading by SYRS's directors and management

2024Q22024Q32024Q42025Q12025Q2−500k−400k−300k−200k−100k0100k200k
Net Shares Purchased by Insiders
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
Revenue Breakdown

SYRS Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
SYRS Income Statement
SYRS Balance Sheet
SYRS Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Mar. 04, 2025
  • Patent Title: Inhibitors of cyclin dependent kinase 7 (cdk7) Mar. 05, 2024
  • Patent Title: Compounds for the modulation of myc activity Sep. 12, 2023
  • Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Sep. 20, 2022
  • Patent Title: Inhibitors of cyclin dependent kinase 7 (cdk7) Apr. 26, 2022
  • Patent Title: Compounds for the modulation of myc activity Mar. 15, 2022
  • Patent Title: Compounds for the modulation of myc activity Sep. 21, 2021
  • Patent Title: Compositions of cyclin dependent kinase 7 (cdk7) inhibitor Aug. 10, 2021
  • Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-α agonists Jul. 06, 2021
  • Patent Title: Pyrrolotriazine compounds and methods of inhibiting tam kinases Jun. 22, 2021
  • Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Dec. 15, 2020
  • Patent Title: Compounds for the modulation of myc activity Sep. 29, 2020
  • Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Aug. 11, 2020
  • Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Jun. 30, 2020
  • Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Dec. 31, 2019
  • Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Jul. 02, 2019
  • Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Jun. 04, 2019
  • Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Mar. 26, 2019
  • Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Jan. 01, 2019
  • Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Oct. 23, 2018
  • Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Aug. 28, 2018
  • Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-α agonists Jan. 16, 2018
  • Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Dec. 19, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
SYRS News

Recent insights relating to SYRS

$SYRS stock is up 126% today. Here's what we see in our data.3/11/2025, 3:30:55 PMArticle Thumbnail
Quiver QuantitativeNew Insider Disclosure: Chee Conley (President & CEO) disclosed 134797 shares sold of $SYRS11/20/2024, 10:17:00 PMArticle Thumbnail
Quiver QuantitativeNew Insider Disclosure: Quirk Gerald E (Chief Legal & Compliance Offic) disclosed 46657 shares sold of $SYRS11/20/2024, 10:17:00 PMArticle Thumbnail
Quiver QuantitativeNew Insider Disclosure: Roth David (Chief Medical Officer) disclosed 12099 shares sold of $SYRS11/20/2024, 10:17:00 PMArticle Thumbnail
Quiver QuantitativeNew Insider Disclosure: Stephens Kristin (Chief Development Officer) disclosed 36133 shares sold of $SYRS11/20/2024, 10:17:00 PMArticle Thumbnail
Quiver QuantitativeNew Insider Disclosure: Haas Jason (Chief Financial Officer) disclosed 137803 shares sold of $SYRS11/20/2024, 10:17:00 PMArticle Thumbnail
Quiver QuantitativeNew Insider Disclosure: Chee Conley (President & CEO) disclosed 100000 shares bought of $SYRS9/12/2024, 9:15:00 PMArticle Thumbnail
Quiver QuantitativeNew Insider Disclosure: Haas Jason (Chief Financial Officer) disclosed 100000 shares bought of $SYRS9/12/2024, 9:15:00 PMArticle Thumbnail
Quiver QuantitativeNew Insider Disclosure: Roth David (Chief Medical Officer) disclosed 10451 shares sold of $SYRS4/5/2024, 8:45:00 PMArticle Thumbnail
Quiver QuantitativeNew Insider Disclosure: Roth David (Chief Medical Officer) disclosed 150 shares sold of $SYRS4/2/2024, 9:01:00 PMArticle Thumbnail
Quiver QuantitativeNew Insider Disclosure: Roth David (Chief Medical Officer) disclosed 6287 shares sold of $SYRS12/14/2023, 9:30:00 PMArticle Thumbnail
Quiver QuantitativeNew Insider Disclosure: Roth David (Chief Medical Officer) disclosed 6287 shares sold of $SYRS12/8/2023, 9:30:00 PMArticle Thumbnail
CNBC Recommendations

Recent picks made for SYRS stock on CNBC

Quiver Logo

No CNBC Picks data for this ticker

CNBC Stock Picks Dashboard
Top ETF Holders

ETFs with the largest estimated holdings in SYRS

Quiver Logo

No ETF data for this ticker

ETF Holdings Dashboard
SYRS Analyst Ratings

SYRS Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
SYRS Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $SYRS stock a Buy, Sell, or Hold?

  • What is the price target for $SYRS stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

SYRS Top Shareholders
Shareholder
Shares Held
SYRS Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $SYRS stock?

  • Who owns the most shares of $SYRS stock?

  • What funds own $SYRS stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

SYRS Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view SYRS Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Bull Case vs Bear Case data is only available to Quiver Premium subscribers.

Back To Top